Search the Health Library
Get the facts on diseases, conditions, tests and procedures.
I Want To...
Find a Doctor
Find a doctor at The Johns Hopkins Hospital, Johns Hopkins Bayview Medical Center or Johns Hopkins Community Physicians.
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
Media Contact: Vanessa Wasta
Scientists at Johns Hopkins have successfully detected ovarian cancer using a blood test for DNA shed by tumors. The test is based on digital analysis of single nucleotide polymorphisms (SNP, or “snips”), in which investigators separate the two strands of code found in every gene to search for imbalances that are a hallmark of cancer cell DNA.
With 54 blood samples from late- and early-stage ovarian cancer patients, the Hopkins team used digital SNP analysis to find so-called “allelic imbalance” in 87 percent (13 out of 15) of early-stage ovarian cancers and 95 percent (37 out of 39) with late-stage disease. No allelic imbalance was detected in 31 blood samples from healthy individuals. The researchers also compared the type of allelic imbalance found in 17 of the samples with the corresponding tumor tissue and found that 15 of these had matching allelic imbalance patterns.
Details of the initial studies of the test are published in the November 20, 2002 issue of the Journal of the National Cancer Institute.
“Digital SNP appears to detect ovarian cancers very well and is far more precise than other available tests,” says Ie-Ming Shih, M.D., Ph.D., assistant professor of Pathology and director of this study for the Kimmel Cancer Center at Johns Hopkins. But, Shih cautioned, digital SNP is too costly and labor intensive at present to serve as a general screening test. “Currently there still is no way to usefully screen all women for ovarian cancer,” Shih says, although it might be useful for women at high risk.
The Hopkins group also is investigating ways of achieving the same accurate detection rate with a less costly, more efficient test that could be used on a broader scale for ovarian and a variety of other cancers, Shih says.
DNA released from dying cells has long been detectable in blood samples, using sensitive molecular technology. But to distinguish normal from cancerous DNA, Kimmel Cancer Center scientists analyzed both sets of genetic code in DNA sequences. The individual sets of code are called alleles. In normal cells, DNA’s two alleles – one derived from the maternal copy of the gene and the other from the paternal copy – are balanced in their basic building blocks. Tumor cells, on the other hand, have an unequal ratio of maternal and paternal alleles. Digital SNP analysis counts the alleles present in each blood sample.
In the Hopkins study, investigators first measured the total amount of DNA in blood samples taken from 44 healthy individuals; 122 patients with a variety of cancers ranging from head and neck cancers to brain cancer, as well as the 54 ovarian cancer patients; and 164 patients with non-cancerous diseases such as diabetes and hypertension. They found that, compared with blood samples of healthy individuals, average amounts of total DNA more than doubled for those with non-cancerous disease (7 ng/mL) but were eight times greater in samples from all cancer patients (59 ng/mL).
“The problem with using the total amount of DNA in the blood without performing digital SNP is that they are not specific for cancer, as elevated DNA levels can be found in blood samples from patients without cancer,” says Shih.
Next, singling out the ovarian cancer samples, Shih and his team found high total amounts of DNA in only 47 percent (7 of 15) early-stage ovarian cancers and 56 percent (22 of 39) with late-stage disease. Adding another test, employing a standard ovarian cancer protein marker (CA125) currently used to monitor disease, added little improvement in detection rates, Shih reported.
“A test based on digital SNP holds promise for improved detection in a wide range of cancers, as well as ovarian cancer, which is currently detected almost always when it is in late stages and difficult to treat,” says Shih.
Ovarian cancer will strike an estimated 23,000 U.S. women and cause approximately 14,000 deaths this year. It ranks fifth in cancer deaths among women. Generally, ovarian cancer is “silent” until the cancer has spread. Women should consult their physicians if they experience pressure or fullness in the pelvis, abdominal bloating, or changes in bowel and bladder patterns that continue and/or worsen.
Funding for this research was provided by the National Cancer Institute and the Richard TeLinde Research Fund.
In addition to Shih, other Johns Hopkins participants in this research include Hsueh-Wei Chang, Shing M. Lee, Steven N. Goodman, Gad Singer, Sarah K. R. Cho, Lori J. Sokoll, Fredrick J. Montz, Richard Roden, Zhen Zhang, Daniel W. Chan, and Robert J. Kurman.
# # #
Chang, Hsueh-Wei et al, “Assessment of Plasma DNA Levels, Allelic Imbalance, and CA125 as Diagnostic Tests for Cancer,” Journal of the National Cancer Institute, Nov. 20, 2002, Vol. 94, No. 22.
On the Web:
Kimmel Cancer Center at Johns Hopkins: www.hopkinskimmelcancercenter.org
Johns Hopkins Kelly Gynecologic Oncology Service: http://womenshealth.jhmi.edu/gynonc/
Johns Hopkins Pathology Ovarian Cancer Web Site: http://ovariancancer.jhmi.edu/home.cfm